Establishing a reference interval for measurement of flux through the mitochondrial fatty acid oxidation pathway in cultured skin fibroblasts.

References 1. Weatherall DJ. The thalassemias. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H, eds. The molecular basis of blood diseases, Vol. 3. Philadelphia: WB Saunders, 2001:183–226. 2. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003;101:791–800. 3. Lemmens-Zygulska M, Eigel A, Helbig B, Sanguansermsri T, Horst J, Flatz G. Prevalence of -thalassemias in northern Thailand. Hum Genet 1996;98: 345–7. 4. Fucharoen S, Winichagoon P, Pootrakul P, Piankijagum A, Wasi P. Differences between two types of Hb H disease, -thalassemia 1/ -thalassemia 2 and -thalassemia 1/Hb constant spring. Birth Defects Orig Artic Ser 1987;23: 309–15. 5. Tan AS, Quah TC, Low PS, Chong SS. A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for -thalassemia. Blood 2001;98:250–1. 6. Waye JS, Eng B, Patterson M, Chui DH, Olivieri NF. Identification of a novel termination codon mutation (TAA3TAT, Term3Tyr) in the 2 globin gene of a Laotian girl with hemoglobin H disease. Blood 1994;83:3418–20. 7. Sanchaisuriya K, Fucharoen G, Fucharoen S. Hb Pakse [( 2) codon 142 (TAA3TAT or Term3Tyr)] in Thai patients with EAbart’s disease and Hb H disease. Hemoglobin 2002;26:227–35. 8. Viprakasit V, Tanphaichitr V, Pung-Amritt P, Petrarat S, Suwantol L, Fisher C, et al. Clinical phenotypes and molecular characterization of Hb H-Pakse disease. Haematologica 2002;87:117–25.